IFA Talks to SoMe Team IFAD2018

Participants and Setting

• Speakers:

  1. Dr. Catherine ("Beni") – A surgical resident posing detailed questions about fluid management.

  2. Dr. Johnny Wilkinson – An intensivist and physiology enthusiast, referencing research trials and discussing fluid strategies.

  3. Additional Colleagues (unnamed) – Intensivists, surgeons, or critical care professionals joining the discussion.

They are at the International Fluid Academy 2018 in Amsterdam, where they discuss advanced fluid-management topics and reflect on conference sessions.

Main Discussion Topics 1. The "Three-Day" Ebb and Flow Rule for Capillary Leak

• Traditional Teaching: Clinicians often cite a three-day period during which capillary permeability peaks (capillary leak), followed by a "closure" or "flow" phase. This is especially mentioned in sepsis and major surgical contexts.

• Open Abdomen & Repeated Surgeries:

  • Dr. Benny wonders if this three-day timeline still applies to trauma patients returning multiple times to the operating room.

  • Key Insight: Repeated insults (new surgeries, infections, "second hits") can prolong capillary leak well beyond three days.

• Individualized Response:

  • The group explains that the "three-day rule" is, at best, a rough guide.

  • Ongoing inflammation, sepsis, or major trauma can stretch the leak over weeks or months. The leak closes only when the underlying cause (e.g., infection, open abdomen) is controlled.

2. Phenotypes and Personalized Therapy

• Emerging Research:

  • Recent studies identify multiple inflammatory phenotypes within conditions like sepsis (some cite five distinct subgroups). Each phenotype could respond differently to fluids, vasopressors, or adjunctive therapies (vitamin C, corticosteroids, albumin, etc.).

• Why Some Trials "Fail":

  • Large RCTs often lump together heterogeneous patient groups, diluting possible benefits of certain treatments for specific phenotypes.

  • Personalized (or "precision") medicine may be needed to target each subtype optimally.

3. Revisiting CVP (Central Venous Pressure)

• CVP Never Disappeared:

  • Although many experts moved away from using CVP as a strict "target" (e.g., 8–12 cmH2O), surveys indicate a majority of ICUs still track it, at least as a data point.

• Utility vs. Pitfalls:

  • CVP can offer trend information: a sudden jump from 8 to 40 likely indicates significant fluid accumulation or cardiac dysfunction.

  • However, a single absolute CVP value is rarely instructive (e.g., "CVP 15 means fluid overload!"). It must be interpreted in context (cardiac function, vascular tone, changes over time, etc.).

• IVC Ultrasound Comparison:

  • Measuring the IVC (inferior vena cava) via ultrasound is akin to looking at "CVP upside down," as both tools ultimately reflect central venous system pressures.

  • The group lightly jokes that heated debates over CVP vs. IVC often obscure their shared physiologic underpinnings.

4. Albumin Use and Oncotic Pressure

• Persistent Controversies:

  • Some clinicians routinely use albumin; others avoid it, citing cost, infection risk, or inconclusive evidence for mortality benefit.

  • Trials and meta-analyses sometimes suggest fluid-sparing effects (i.e., patients may require less total fluid), but whether that translates into improved outcomes remains uncertain.

• Oncotic Pressure & Glycocalyx:

  • The group mentions the glycocalyx and evolving views on how fluids distribute within the body. Traditional concepts of "oncotic pressure" have been challenged, as measuring it is difficult and the capillary barrier is more complex than once thought.

  • They caution that lab-based findings on glycocalyx or oncotic pressure don't easily translate into everyday bedside decision-making.

5. Conference Highlights and Personal Takeaways

• Evolving Understanding:

  • Dr. Beni appreciates learning that her own confusion reflects the field's genuine complexity; there is no universal formula for fluid management.

  • The conversation reaffirms the value of building a "personal learning network" to share insights and questions with peers.

• Heated Debates:

  • The group enjoys spirited disagreements among conference presenters (e.g., conflating ICU and elective surgery data).

  • They praise the event for turning a "dry topic" like fluid therapy into dynamic, engaging discussions.

Key Takeaways

1. No Strict "Three-Day" Timeline

   • The notion that capillary leak automatically resolves by day three is too simplistic—many variables, like persistent inflammation, repeated surgical interventions, and individual phenotypes, can prolong or alter this process.

2. Precision Medicine in Fluid Therapy

   • Different inflammatory phenotypes and patient contexts (e.g., sepsis vs. trauma) might require tailored therapies. This explains why broad clinical trials often produce mixed or inconclusive results.

3. CVP: Still Relevant, but Context Matters

   • Monitoring and trending CVP can offer valuable clues, yet it should not be used in isolation. It's best interpreted alongside clinical assessment, point-of-care ultrasound, and other hemodynamic data.

4. Albumin Use is Nuanced

   • Research is mixed about when albumin confers an advantage over crystalloids. Many clinicians do use it—often for fluid-sparing reasons—yet conclusive evidence for mortality or strong outcome benefits remains elusive.

   • Cost, supply considerations, and possible infection risk also factor into decisions.

5. Benefit of Open Debate

   • The group appreciates conference sessions that stimulate robust arguments, recognizing it advances the conversation and highlights the complexity of fluid management.

Concluding Note

This transcript offers a window into current fluid-management debates, including capillary leak timelines, CVP's evolving role, and the uncertain but ongoing place of albumin in critical care. Above all, it underscores that individual patient factors—from genetic phenotypes to clinical context—drive decisions more reliably than any single guideline or laboratory concept.